Given the heterogeneous expression of HER-2/neu in cervical carcinoma, a multidisciplinary approach integrating molecular diagnostics, histopathological evaluation, and clinical staging is crucial for accurate prognostication and treatment planning. Here, ERBB2 is linked to cervical carcinoma.